volasertib
Small moleculeexperimental
Volasertib is an experimental small molecule inhibitor of the PLK1 protein being developed by Boehringer Ingelheim for use as an anti-cancer agent. Volasertib is the second in a novel class of drugs called dihydropteridinone derivatives. — Wikipedia
Clinical trial activity
26 trials · 11 clinical orgs · 0 marketing orgs
Phase 1
20
Phase 2
6
Phase 3
1
Phase 4
0
Earliest trial started Nov 1, 2005 (NCT02273388)
Timeline
Indications
Studied for
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Leukemia · Phase 1
- Leukemia, Erythroblastic, Acute · Phase 1
- Leukemia, Megakaryoblastic, Acute · Phase 1
- Leukemia, Monocytic, Acute · Phase 1
- Leukemia, Myeloid, Acute · Phase 3
- Leukemia, Myelomonocytic, Acute · Phase 1
- Leukemia, Myelomonocytic, Chronic · Phase 1
- Lymphoma · Phase 1
- Lymphoma, T-Cell · Phase 1
- Lymphoma, T-Cell, Cutaneous · Phase 1
- Lymphoma, T-Cell, Peripheral · Phase 1
- Myelodysplastic Syndromes · Phase 2
- Neoplasms · Phase 2
- Ovarian Neoplasms · Phase 2
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma · Phase 1
Mechanism of action
- Serine/threonine-protein kinase PLK1INHIBITOR
PLK1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)N[C@H]4CC[C@H](N5CCN(CC6CC6)CC5)CC4)cc3OC)nc2N1C(C)C- Mol. weight
- 618.83 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaVolasertib ↗
- ChEMBLCHEMBL1233528 ↗
Also known as
- bi 6727
- bi 6727
- bi 6727
- bi-6727
- bi-6727
- bi-6727
- bi-6727
- volasertib
- volasertib
- volasertib
- volasertib
- volasertib
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02722135 | Phase 1 | Nov 1, 2016 | Boehringer Ingelheim |
| NCT02527174 | Phase 1 | Nov 1, 2016 | University of Alberta |
| NCT02757248 | Phase 1 | Nov 1, 2016 | Boehringer Ingelheim, Duke University, National Comprehensive Cancer Network |
| NCT02875002 | Phase 1 | Oct 1, 2016 | Johns Hopkins University, Virginia Commonwealth University, Yale University |
| NCT02905994 | Phase 1 | Sep 1, 2016 | Boehringer Ingelheim, Harvard University |
| NCT02861040 | Phase 1 | Aug 1, 2016 | National Cancer Institute (NCI), National Comprehensive Cancer Network, Northwestern University |
| NCT02721875 | Phase 1 | Apr 1, 2016 | Boehringer Ingelheim |
| NCT02198482 | Phase 2 | Feb 1, 2016 | University of Ulm |
| NCT02201329 | Phase 1 | Aug 1, 2014 | Boehringer Ingelheim |
| NCT02003573 | Phase 1 | Jan 1, 2014 | Boehringer Ingelheim |
| NCT01957644 | Phase 1 | Nov 1, 2013 | Boehringer Ingelheim |
| NCT01971476 | Phase 1 | Oct 1, 2013 | Boehringer Ingelheim |
| NCT01772563 | Phase 1 | Feb 4, 2013 | Boehringer Ingelheim |
| NCT01721876 | Phase 3 | Jan 1, 2013 | Boehringer Ingelheim |
| NCT01662505 | Phase 1 | Aug 1, 2012 | Boehringer Ingelheim |
| NCT01348347 | Phase 1 | Apr 1, 2011 | Boehringer Ingelheim |
| NCT01206816 | Phase 1 | Oct 1, 2010 | Boehringer Ingelheim |
| NCT01145885 | Phase 1 | Jun 1, 2010 | Boehringer Ingelheim |
| NCT01121406 | Phase 2 | Apr 1, 2010 | Boehringer Ingelheim |
| NCT01022853 | Phase 1 | Dec 1, 2009 | Boehringer Ingelheim |
Showing 20 of 26 trials
Page 1 / 2
Organizations
Research & Development (11)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Boehringer Ingelheim | For profit | 22 | 20 | 3 | 2005 |
| National Comprehensive Cancer Network | Academic/Hospital | 2 | 0 | 1 | 2016 |
| Duke University | Academic/Hospital | 1 | 1 | 1 | 2016 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2016 |
| Johns Hopkins University | Academic/Hospital | 1 | 0 | 1 | 2016 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2016 |
| Northwestern University | Academic/Hospital | 1 | 1 | 1 | 2016 |
| University of Alberta | Academic/Hospital | 1 | 1 | 1 | 2016 |
| University of Ulm | Academic/Hospital | 1 | 1 | 1 | 2016 |
| Virginia Commonwealth University | Academic/Hospital | 1 | 0 | 1 | 2016 |
| Yale University | Academic/Hospital | 1 | 1 | 1 | 2016 |
11 organizations
Page 1 / 1